Hepatitis B Virus (HBV) Therapeutics - Current and Future Players


#724080

84pages

GlobalData

$ 2995

In Stock

Hepatitis B Virus (HBV) Therapeutics - Current and Future Players

Summary

GlobalData has released its pharma report, Hepatitis B Virus (HBV) Therapeutics - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing HBV Market. The report identifies and analyses the key companies shaping and driving the global HBV market. The report provides insight into the competitive HBV landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for HBV
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of HBV sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving HBV market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- Whats the next big thing in the global HBV market landscape? Identify,
- Understand and capitalize
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Market Outlook
3.1 Global Markets
3.1.1 Forecast
3.1.2 Drivers and Barriers - Global Issues
4 Current and Future Players
4.1 Overview
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.1 Gilead
4.3.2 Bristol-Myers Squibb
4.3.3 Roche
4.3.4 Merck
4.3.5 GSK
4.3.6 Novartis
4.3.7 Arrowhead Research
4.3.8 GlobeImmune
5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Methodology
5.4 Forecasting Methodology
5.4.1 Total Prevalent Cases of Chronic Hepatitis B
5.4.2 Diagnosed Chronic Hepatitis B Patients
5.4.3 Percent Drug-Treated Chronic Hepatitis B Patients
5.4.4 Drugs Included in Each Therapeutic Class
5.4.5 Launch and Patent Expiry Dates
5.4.6 General Pricing Assumptions
5.4.7 Individual Drug Assumptions
5.4.8 Generic Erosion
5.4.9 Pricing of Pipeline Agents
5.5 Primary Research - KOLs Interviewed for this Report
5.6 Primary Research - Prescriber Survey
5.7 About the Authors
5.7.1 Analyst
5.7.2 Therapy Area Director
5.7.3 Epidemiologists
5.7.4 Global Director of Therapy Analysis and Epidemiology
5.7.5 Global Head of Healthcare
5.8 About GlobalData
5.9 Disclaimer

1.1 List of Tables
Table 1: Global Sales Forecasts ($m) for Chronic Hepatitis B Therapeutics, 2014-2024
Table 2: Chronic Hepatitis B Therapeutics Market - Drivers and Barriers, 2014-2024
Table 3: Key Companies in the Chronic Hepatitis B Therapeutics Market, 8MM, 2015
Table 4: Gileads Chronic Hepatitis B Portfolio Assessment, 2015
Table 5: BMSs Chronic Hepatitis B Portfolio Assessment, 2015
Table 6: Roches Chronic Hepatitis B Portfolio Assessment, 2015
Table 7: Mercks Chronic Hepatitis B Portfolio Assessment, 2015
Table 8: GSKs Chronic Hepatitis B Portfolio Assessment, 2015
Table 9: Novartis Chronic Hepatitis B Portfolio Assessment, 2015
Table 10: Arrowheads Chronic Hepatitis B Portfolio Assessment, 2015
Table 11: GlobeImmunes Chronic Hepatitis B Portfolio Assessment, 2015
Table 12: Key Historical and Projected Launch Dates
Table 13: Key Historical and Projected Patent Expiry Dates
Table 14: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Sales for Chronic Hepatitis B Therapeutics by Country, 2014-2024
Figure 2: Sales for Chronic Hepatitis B Therapeutics by Therapy Class, 2014-2024
Figure 3: Company Portfolio Gap Analysis in the Chronic Hepatitis B Therapeutic Market, 2014-2024